Moleculin Biotech, Inc. has announced the grant of an Australian patent that strengthens its intellectual property protection for a key aspect of its Annamycin formulation technology. This development is crucial for the company as it enhances its competitive position in the pharmaceutical preparations industry.

On November 12, 2026, Moleculin disclosed the patent's approval, which covers the preparation of preliposomal Annamycin lyophilizate. This patent was granted to Moleculin in collaboration with The Board of Regents of The University of Texas System.

Background

Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing treatments for difficult-to-treat tumors and viruses. The company operates under the Standard Industrial Classification (SIC) code 2834, which pertains to Pharmaceutical Preparations. Moleculin trades on the Nasdaq under the ticker symbol MBRX.

What the Filing Says

The filing states, "On November 12, 2026, Moleculin Biotech, Inc. announced the grant of an Australian patent covering the preparation of preliposomal Annamycin lyophilizate, strengthening the Company’s intellectual property protection for a key aspect of Annamycin’s formulation technology." Additionally, the patent is numbered 2020303572.

Impact

This patent grant may significantly affect Moleculin's ongoing clinical development efforts for Annamycin, an investigational anthracycline aimed at treating acute myeloid leukemia (AML) and other challenging cancers. The enhanced intellectual property protection could also bolster investor confidence and attract potential partnerships.

What's Next

The filing does not say what happens next.